(Q39359343)

11 September 2017

title

Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma (English)

1 reference

11 September 2017

1

1 reference

11 September 2017

Paolo Giovanni Casali

series ordinal

2

1 reference

11 September 2017

5

Axel Le Cesne

0 references

author name string

Antonio Nieto

series ordinal

3

1 reference

11 September 2017

Adnan Tanović

series ordinal

4

1 reference

11 September 2017

language of work or name

English

0 references

publication date

29 August 2013

1 reference

11 September 2017

1 reference

11 September 2017

volume

10

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

59-68

1 reference

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

A review of trabectedin (ET-743): a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

New agents for the treatment of lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Trabectedin therapy for sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.163

21 January 2018

Identifiers

DOI

10.2217/FON.13.163

1 reference

11 September 2017

1 reference